Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 4:35 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | Hillhouse Capital Management Ltd. | 6,657,030 5.100% | 6,657,030 (New Position) | View |
| 2024-11-14 1:42 pm Sale | 13G | Cytek Biosciences, Inc. CTKB | BROWN CAPITAL MANAGEMENT LLC | 9,493,474 7.220% | -2,522,851 (-21.00%) | View |
| 2024-02-22 7:07 pm Unchanged | 13G | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 6,809,404 5.200% | 0 (Unchanged) | View |
| 2024-02-14 4:39 pm Sale | 13G | Cytek Biosciences, Inc. CTKB | HHLR ADVISORS LTD. | 6,657,030 4.900% | -2,027,500 (-23.35%) | View |
| 2024-02-14 4:08 pm Sale | 13G | Cytek Biosciences, Inc. CTKB | Yan Ming | 6,203,867 4.700% | -1,999,491 (-24.37%) | View |
| 2024-02-14 4:07 pm Sale | 13G | Cytek Biosciences, Inc. CTKB | Jiang Wenbin | 5,702,130 4.300% | -2,318,353 (-28.91%) | View |
| 2024-02-14 3:12 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | BROWN CAPITAL MANAGEMENT LLC | 12,016,325 8.860% | 12,016,325 (New Position) | View |
| 2024-02-13 5:02 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | VANGUARD GROUP INC | 11,890,700 8.770% | 4,119,633 (+53.01%) | View |
| 2024-01-23 4:13 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 17,779,753 13.100% | 2,944,538 (+19.85%) | View |
| 2023-09-19 5:25 pm Sale | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 6,809,404 4.990% | -6,329,923 (-48.18%) | View |
| 2023-05-05 11:52 am Purchase | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 14,835,215 10.900% | 6,467,608 (+77.29%) | View |
| 2023-02-14 4:09 pm Sale | 13G | Cytek Biosciences, Inc. CTKB | HHLR ADVISORS LTD. | 8,684,530 6.400% | -72,500 (-0.83%) | View |
| 2023-02-09 11:16 am Purchase | 13G | Cytek Biosciences, Inc. CTKB | VANGUARD GROUP INC | 7,771,067 5.760% | 7,771,067 (New Position) | View |
| 2023-02-03 12:10 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | BlackRock Inc. BLK | 8,367,607 6.200% | 8,367,607 (New Position) | View |
| 2022-08-03 5:26 pm Sale | 13G | Cytek Biosciences, Inc. CTKB | 3E Bioventures Capital L.P. | 5,684,615 4.230% | -4,002,250 (-41.32%) | View |
| 2022-03-14 5:04 pm Purchase | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 13,139,327 9.800% | 2,057,164 (+18.56%) | View |
| 2022-02-28 5:29 pm Purchase | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 11,082,163 8.300% | 1,475,135 (+15.35%) | View |
| 2022-02-16 6:27 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | 3E Bioventures Capital L.P. | 9,686,865 7.240% | 9,686,865 (New Position) | View |
| 2022-02-14 4:09 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | HHLR ADVISORS LTD. | 8,757,030 6.500% | 8,757,030 (New Position) | View |
| 2022-02-14 2:04 pm Purchase | 13G | Cytek Biosciences, Inc. CTKB | Jiang Wenbin | 8,020,483 5.990% | 8,020,483 (New Position) | View |